Mark Stejbach has been appointed chief commercial officer at Alkermes. In this newly created role, Mr. Stejbach will be responsible for commercial activities, including marketing and sales of Vivitrol (naltrexone for extended-release injectable suspension) and developing commercial strategies for Alkermes’ late-stage pipeline, namely ALKS 9070 (for schizophrenia), ALKS 37 (for opioid-induced constipation) and ALKS 5461 (for treatment-resistant depression). Mr. Stejbach will also serve on the exe...